1. H Al-Mondhiry 1983 Beta thromboglobulin and platelet factor 4 in patients with cancer Am J Hematol 14 105.

1. H Al-Mondhiry 1983 Beta thromboglobulin and platelet factor 4 in patients with cancer Am J Hematol 14 105.)| false
• Search Google Scholar
• Export Citation

2. UH Athale AKC Chan 2007 Thromboembolic complications in pediatric hematologic malignancies Semin Thromb Hemost 33 416 426.

2. UH Athale AKC Chan 2007 Thromboembolic complications in pediatric hematologic malignancies Semin Thromb Hemost 33 416 426.)| false
• Search Google Scholar
• Export Citation

3. T Barbui G Finazzi 1999 Management of essential thrombocythemia Crit Rev Oncol Hematol 29 257 266.

3. T Barbui G Finazzi 1999 Management of essential thrombocythemia Crit Rev Oncol Hematol 29 257 266.)| false
• Search Google Scholar
• Export Citation

4. CL Bennett CC Tigue BA Angelotta 2007 Adverse effect of drugs used to treat hematologic malignancies: Surveillance Effort from the Research on Adverse Drug Events and Reports Project Semin Thromb Hemost 33 365 372.

4. CL Bennett CC Tigue BA Angelotta 2007 Adverse effect of drugs used to treat hematologic malignancies: Surveillance Effort from the Research on Adverse Drug Events and Reports Project Semin Thromb Hemost 33 365 372.)| false
• Search Google Scholar
• Export Citation

5. MC Bertomeu S Gallo D Lauri 1990 Chemotherapy enhances endothelial reactivity to platelets Clin Exp Metast 8 511 518.

5. MC Bertomeu S Gallo D Lauri 1990 Chemotherapy enhances endothelial reactivity to platelets Clin Exp Metast 8 511 518.)| false
• Search Google Scholar
• Export Citation

6. JF Bohlius S Langensiepen A Engert 2005 Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review Best Pract Res Clin Haematol 18 449 454.

6. JF Bohlius S Langensiepen A Engert 2005 Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review Best Pract Res Clin Haematol 18 449 454.)| false
• Search Google Scholar
• Export Citation

7. PF Bross J Beitz G Chen 2001 Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin Cancer Res 7 1490 1496.

7. PF Bross J Beitz G Chen 2001 Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin Cancer Res 7 1490 1496.)| false
• Search Google Scholar
• Export Citation

8. L Canobbio F Boccardo D Guarneri 1991 Phase II study of navelbine in advanced renal cell carcinoma Eur J Cancer Clin Oncol 27 804 805.

8. L Canobbio F Boccardo D Guarneri 1991 Phase II study of navelbine in advanced renal cell carcinoma Eur J Cancer Clin Oncol 27 804 805.)| false
• Search Google Scholar
• Export Citation

9. VA Carrol BR Binder 1999 The role of the plasminogen activation system in cancer Semin Thromb Hemost 25 183 197.

9. VA Carrol BR Binder 1999 The role of the plasminogen activation system in cancer Semin Thromb Hemost 25 183 197.)| false
• Search Google Scholar
• Export Citation

10. NH Dang FB Hagemeister B Pro 2004 Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 22 4095 4102.

10. NH Dang FB Hagemeister B Pro 2004 Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 22 4095 4102.)| false
• Search Google Scholar
• Export Citation

11. A Falanga M Marchetti T Barbui 2002 All-trans-retinoic acid and bleeding/thrombosis Pathophysiol Haemost Thromb 1 Suppl 19 21.

11. A Falanga M Marchetti T Barbui 2002 All-trans-retinoic acid and bleeding/thrombosis Pathophysiol Haemost Thromb 1 Suppl 19 21.)| false
• Search Google Scholar
• Export Citation

12. A Falanga M Marchetti 2007 Heparin in tumor progression and metastatic dissemination Semin Thromb Hemost 33 688 694.

12. A Falanga M Marchetti 2007 Heparin in tumor progression and metastatic dissemination Semin Thromb Hemost 33 688 694.)| false
• Search Google Scholar
• Export Citation

13. A Falanga FR Rickles 1999 Pathophysiology of the thrombophilic state in the cancer patient Semin Thromb Hemost 25 173 182.

13. A Falanga FR Rickles 1999 Pathophysiology of the thrombophilic state in the cancer patient Semin Thromb Hemost 25 173 182.)| false
• Search Google Scholar
• Export Citation

14. P Fernandez SR Patierno FR Rickles 2004 Tissue factor and fibrin in tumor angiogenesis Semin Thromb Hemost 30 31 44.

14. P Fernandez SR Patierno FR Rickles 2004 Tissue factor and fibrin in tumor angiogenesis Semin Thromb Hemost 30 31 44.)| false
• Search Google Scholar
• Export Citation

15. BD Humphreys JP Sharman JM Henderson 2004 Gemcitabine-associated thrombotic microangiopathy Cancer 100 2664 2670.

15. BD Humphreys JP Sharman JM Henderson 2004 Gemcitabine-associated thrombotic microangiopathy Cancer 100 2664 2670.)| false
• Search Google Scholar
• Export Citation

16. AK Kakkar AR Hedges CR Williamson 1995 Perioperative heparin therapy increases late deaths from metastatic cancer Int J Oncol 6 885 888.

16. AK Kakkar AR Hedges CR Williamson 1995 Perioperative heparin therapy increases late deaths from metastatic cancer Int J Oncol 6 885 888.)| false
• Search Google Scholar
• Export Citation

17. AA Khorana RL Fine 2004 Pancreatic cancer and thromboembolic disease Lancet Oncol 5 655 663.

17. AA Khorana RL Fine 2004 Pancreatic cancer and thromboembolic disease Lancet Oncol 5 655 663.)| false
• Search Google Scholar
• Export Citation

18. MD Kohli V Kaushal P Mehta 2003 Role of coagulation and fibrinolytic system in prostate cancer Semin Thromb Hemost 29 301 308.

18. MD Kohli V Kaushal P Mehta 2003 Role of coagulation and fibrinolytic system in prostate cancer Semin Thromb Hemost 29 301 308.)| false
• Search Google Scholar
• Export Citation

19. O Kucuk HC Kwaan W Gunnar RM Vazquez 1985 Thromboembolic complication associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma Cancer 55 702 706.

19. O Kucuk HC Kwaan W Gunnar RM Vazquez 1985 Thromboembolic complication associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma Cancer 55 702 706.)| false
• Search Google Scholar
• Export Citation

20. HC Kwaan S Palmar J Wang 2003 Pathogenesis of increased risk of thrombosis in cancer Semin Thromb Hemost 29 283 290.

20. HC Kwaan S Palmar J Wang 2003 Pathogenesis of increased risk of thrombosis in cancer Semin Thromb Hemost 29 283 290.)| false
• Search Google Scholar
• Export Citation

21. AYY Lee 1999 The thrombophilic state induced by therapeutic agents in the cancer patient Semin Thromb Hemost 25 137 146.

21. AYY Lee 1999 The thrombophilic state induced by therapeutic agents in the cancer patient Semin Thromb Hemost 25 137 146.)| false
• Search Google Scholar
• Export Citation

22. S Lentzsch R LeBlanc K Podar 2003 Immunomodulatory analogues of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo Lancet 17 41 44.

22. S Lentzsch R LeBlanc K Podar 2003 Immunomodulatory analogues of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo Lancet 17 41 44.)| false
• Search Google Scholar
• Export Citation

23. J Litz G Sakuntala Warshamana-Greene G Sulanke 2004 The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression Lung Cancer 46 283 291.

23. J Litz G Sakuntala Warshamana-Greene G Sulanke 2004 The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression Lung Cancer 46 283 291.)| false
• Search Google Scholar
• Export Citation

24. Magyar Thrombosis és Haemostasis Társaság Konszenzus Nyilatkozata a Thromboemboliás megbetegedések prevenciója és kezelése tárgyában. Szerk: Pfliegler Gy és mtsai, Hematológiai Transzfuziológia S2:3-46, 2005.

24. Magyar Thrombosis és Haemostasis Társaság Konszenzus Nyilatkozata a Thromboemboliás megbetegedések prevenciója és kezelése tárgyában. Szerk: Pfliegler Gy és mtsai, Hematológiai Transzfuziológia S2:3-46, 2005.)| false
• Search Google Scholar
• Export Citation

25. PA Martorana H Göbel M Just RE Nitz 1986 Effect of molsidomine on platelet-mediated thrombosis in stenosed canine coronary arteries J Mol Cell Cardiol 18 Suppl 1 100.

25. PA Martorana H Göbel M Just RE Nitz 1986 Effect of molsidomine on platelet-mediated thrombosis in stenosed canine coronary arteries J Mol Cell Cardiol 18 Suppl 1 100.)| false
• Search Google Scholar
• Export Citation

26. K Miralem 1996 Antiangiogenic properties of heparins J Biol Chem 271 17100 17106.

26. K Miralem 1996 Antiangiogenic properties of heparins J Biol Chem 271 17100 17106.)| false
• Search Google Scholar
• Export Citation

27. J Pander H Gelderblom HJ Guchelaar 2007 Pharmacogenetics of EGFR and VEGF inhibition Drug Discovery Today 12 1054 1060.

27. J Pander H Gelderblom HJ Guchelaar 2007 Pharmacogenetics of EGFR and VEGF inhibition Drug Discovery Today 12 1054 1060.)| false
• Search Google Scholar
• Export Citation

28. R Pérez-Soler A Chachoua LA Hammond 2004 Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 3238 3247.

28. R Pérez-Soler A Chachoua LA Hammond 2004 Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 3238 3247.)| false
• Search Google Scholar
• Export Citation

29. JP Pujol JL Breton R Gervais 2007 Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC J Clin Oncol 25 3945 3951.

29. JP Pujol JL Breton R Gervais 2007 Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC J Clin Oncol 25 3945 3951.)| false
• Search Google Scholar
• Export Citation

30. P Rajvanshi HM Shulman EL Sievers GB McDonald 2002 Hepatic sinusoidal obstruction after gemtuzumab ozogamicin therapy Blood 99 23010 23014.

30. P Rajvanshi HM Shulman EL Sievers GB McDonald 2002 Hepatic sinusoidal obstruction after gemtuzumab ozogamicin therapy Blood 99 23010 23014.)| false
• Search Google Scholar
• Export Citation

31. C Rella M Coviello M Quaranta A Paradiso 1993 Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer Thromb Res 69 209 220.

31. C Rella M Coviello M Quaranta A Paradiso 1993 Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer Thromb Res 69 209 220.)| false
• Search Google Scholar
• Export Citation

32. T Shapner DC Tormey R Gray 1991 Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer J Clin Oncol 9 286 294.

32. T Shapner DC Tormey R Gray 1991 Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer J Clin Oncol 9 286 294.)| false
• Search Google Scholar
• Export Citation

33. MR Sherman FB Tuazon LK Miller 1980 Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol Endocrinol 106 1715 1727.

33. MR Sherman FB Tuazon LK Miller 1980 Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol Endocrinol 106 1715 1727.)| false
• Search Google Scholar
• Export Citation

34. S Simonneau S Lapota P Mismetti 2006 A randomised study comparing the efficacy and safety of nadroparine 2850 UI vs. enoxaparine 4000 UI in the prevention of venous thromboembolism after colorectal surgery for cancer J Thromb Hemost 4 1693 1700.

34. S Simonneau S Lapota P Mismetti 2006 A randomised study comparing the efficacy and safety of nadroparine 2850 UI vs. enoxaparine 4000 UI in the prevention of venous thromboembolism after colorectal surgery for cancer J Thromb Hemost 4 1693 1700.)| false
• Search Google Scholar
• Export Citation

35. S Singhal J Mehta 2002 Thalidomide in cancer Biomed Pharmacother 56 4 12.

35. S Singhal J Mehta 2002 Thalidomide in cancer Biomed Pharmacother 56 4 12.)| false
• Search Google Scholar
• Export Citation

36. NE Tsopanoglu ME Maragoudakis 2004 Role of thrombin in angiogenesis and tumor progression Semin Thromb Hemost 30 63 70.

36. NE Tsopanoglu ME Maragoudakis 2004 Role of thrombin in angiogenesis and tumor progression Semin Thromb Hemost 30 63 70.)| false
• Search Google Scholar
• Export Citation

37. LD Wagman MF Baird CL Bennett 2006 Venous thromboembolic disease. Clinical practice guidelines in oncology J Natl Compr Canc Netw 4 838 869.

37. LD Wagman MF Baird CL Bennett 2006 Venous thromboembolic disease. Clinical practice guidelines in oncology J Natl Compr Canc Netw 4 838 869.)| false
• Search Google Scholar
• Export Citation

38. MZ Wojtukiewicz E Sierko Z Sawicki 2007 Expression of tissue factor (TF), tissue factor pathway inhibitor (TFPI), factor IX and factor X in breast cancer: comparison between primary tumor and metastatic lesions in regional lymph nodes Thromb Res 120 Suppl 2 S154.

38. MZ Wojtukiewicz E Sierko Z Sawicki 2007 Expression of tissue factor (TF), tissue factor pathway inhibitor (TFPI), factor IX and factor X in breast cancer: comparison between primary tumor and metastatic lesions in regional lymph nodes Thromb Res 120 Suppl 2 S154.)| false
• Search Google Scholar
• Export Citation

39. A Zakarija HC Kwaan 2007 Adverse effects of hemostatic function of drugs used in hematologic malignancies Semin Thromb Hemost 33 355 364.

39. A Zakarija HC Kwaan 2007 Adverse effects of hemostatic function of drugs used in hematologic malignancies Semin Thromb Hemost 33 355 364.)| false
• Search Google Scholar
• Export Citation